FUSION ANTIBODIES PLC (FAB) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the FUSION ANTIBODIES PLC Investor Presentation. We begin, I'd like to submit the following poll. Now I'd to hand you over to the management team, Adrian. Good morning, sir. Good morning. Thank you, Charlie. So my name is Adrian Kincaid. I'm the CEO of FUSION ANTIBODIES. I'm joined today by Steven Smith, who is our interim CFO, although has been with us for quite a while now. So welcome, Steven. Thanks for all the support. So we're going to take you through the results presentation for the year ended March 31 following the full audit required, and much of the the results have actually been out since we did the trading update, but now they're they're audited. So we'll follow the the usual format, and I just need to remind you of our legal obligations and the disclaimer that's on screen here. Thank you very much for me reading it. And I'll hand over to Steven to take us through the income statement. Thank you, Adrian. Yeah. And by way of introduction, as Adrian said, I'm Steven Smith. I'm the interim CFO at FUSION. So our interim, our income statement extract, for the financial year ending March 3126, showed revenue increasing by 7% to just over GBP 2,100,000 in the financial year. It's important to add that there was this revenue for 2026 did include a one off GBP 2 and 50,000 IP transaction, with, Finn Therapeutics. So there was £250,000 of revenue that was, I suppose, outside of our, I wouldn't say our normal scope, but outside of our previous activity, in the current financial year. So if we exclude that, IP transaction, other operational revenues were down marginally, year on year, which, I think, reflecting continued pressures across the biotech funding environment. And what we've seen is a longer customer decision making cycle from discu...